Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2026-A00510-51 | Other Identifier | Nantes Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study evaluates a Clinical Decision Support System (CDSS), named PRIMUS, designed to support therapeutic decision-making in MS. The CDSS is based on a validated reference database integrating retrospective data from randomized controlled trials and the French national MS cohort (Observatoire Français de la Sclérose en Plaques, OFSEP). This reference database consists of synthetic data derived from these sources.
PRIMUS enables visualization of disease activity at 1 and 2 years under different therapeutic scenarios, based on clinical and MRI characteristics of patients similar to the patient of interest. The CDSS PRIMUS aims to support informed and individualized treatment decisions. Because MRI is a critical marker of disease activity previously acquired MRI scans will be reanalyzed using automated segmentation and validated by a radiologist to standardize lesion assessment across centers. The results will be displayed to the neurologist and, if appropriate shown to the patient using a dedicated viewer, and can be discussed during the consultation.
A cluster-randomized controlled trial, with hospitals as the unit, will be conducted to evaluate the impact of the CDSS on treatment decision-making in patients with relapsing-remitting MS. The primary objective is to assess whether the use of the CDSS influences therapeutic choices during clinical consultations.
The study hypothesis is that use of the CDSS will increase the proportion of high-efficacy treatments initiated or selected, compared with usual care without CDSS support.
In parallel, an optional sub-study using a mixed-methods approach will explore clinicians' and patients' perceptions of, and interactions with, the CDSS.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Consultation with clinical decision support system CDSS | Experimental | Participants will undergo a consultation supported by a CDSS when initiation or modification of MS treatment is being considered. |
|
| Usual care (consultation without CDSS) | No Intervention | Participants will receive standard clinical care without the use of a Clinical Decision Support System (CDSS). Treatment decisions will be made according to routine clinical practice. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Clinical decision support system | Device | The Clinical Decision Support System (CDSS) PRIMUS is a software (as medical device) designed to support therapeutic decisions in multiple sclerosis (MS) and assist clinicians during consultations in which initiation or modification of MS treatment is considered. The system uses retrospective clinical and MRI data from a reference database to generate visualizations of disease evolution over a 2-year period under different therapeutic scenarios, based on patient-specific characteristics entered by the clinician. PRIMUS does not make treatment recommendations and does not replace clinical judgment. All treatment decisions remain at the discretion of the clinician |
| Measure | Description | Time Frame |
|---|---|---|
| Treatment choice | Treatment decision at the end of the consultation with or without CDSS use. Patients will be classified into groups: high-efficacy disease-modifying therapies (anti-CD20 therapies, natalizumab, cladribine, S1P receptor modulators), moderate-efficacy therapies (interferon beta, dimethyl fumarate, teriflunomide), or no treatment. Results will be expressed as the percentage of patients in each category/ The distribution of treatment strategies will be expressed as the percentage of patients in each category. | once at Month 1 |
| Measure | Description | Time Frame |
|---|---|---|
| Treatment decision concordance with expert recommendation | Assessment of concordance defined as agreement (Yes/no) between the treatment decision made by the neurologist at the end of the consultation (Month 1, with or without CDSS use) and the treatment decision recommended by an independent expert panel of experts. | Month 1 |
Not provided
Inclusion Criteria:
Men and women aged >18 and ≤50 years.
Patients with relapsing-remitting multiple sclerosis (RRMS) according to the McDonald 2024 criteria.
Patients for whom a change in therapeutic management is being considered due to:
intolerance to treatment or personal preference in the absence of inflammatory activity, whether patients are:
recent inflammatory activity (relapse or at least one T1 Gd+ lesion or one new T2 lesion) reported or observed at inclusion, whether patients are:
Patients with MRI follow-up including at least one 3D brain FLAIR sequence and a T1 Gd+ sequence in the case of a re-baseline brain MRI within the past 6 months.
Patients whose MRI scans are available for download on the day of consultation.
Patients affiliated with or beneficiaries of a social security system.
Patients able to provide written informed consent. For women of childbearing potential, use of an effective method of contraception throughout the study in accordance with the recommendations of the Clinical Trials Coordination Group
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| David M LAPLAUD, Professor | Contact | 02 40 16 52 85 | david.laplaud@chu-nantes.fr | |
| Selma Mrs EL ANDALOUSSI, Project Manager | Contact | 0253482852 | selma.elandaloussi@chu-nantes.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Angers Hospital | Angers | 49933 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study uses a cluster-randomized design with hospital (where the patient receives MS care) as cluster. Each center will be randomly allocated in a 1:1 ratio to experimental group (using CDSS/ use of the CDSS during the consultation), control group (receive usual care).The study is conducted in an open-label manner, with both patients and treating physicians aware of CDSS use.
Not provided
Not provided
Not provided
Not provided
|
| Patient Adherence: Concordance Between Prescribed and Actual Treatment |
Assessment of concordance (yes/no) between the treatment decision made by the neurologist at the end of the consultation (Month 1, with or without CDSS use) and the treatment actually taken by the patient at Month 10. |
| Month 10, last visit |
| Treatment Decision Concordance with Dynamic Score Recommendation | Assessment of concordance defined as agreement (yes/no) between the treatment decision made by the neurologist at the end of the consultation (M1, with or without CDSS use) and recommendations derived from a dynamic scoring system designed to guide early switching from first-line to second-line disease-modifying therapy in patients with relapsing-remitting MS.For this outcome measure, results will be reported as the proportion of participants whose treatment decision is concordant with the recommendation generated by the dynamic score (Yes/No).The dynamic score is based on predefined clinical and radiological criteria and identifies patients who may benefit from early treatment escalation to reduce the risk of relapse.The recommendation generated by the score (maintain first-line therapy or escalate to second-line therapy) will be compared to the neurologist's treatment decision.Concordance will be considered achieved if the neurologist's treatment decision matches the recommendations | Month 1 |
| Evolution of treatment decision | Assessment of concordance defined as agreement (yes/no) between the treatment decision initially considered by the neurologist at inclusion (Month 0) and the treatment decision made at the end of the consultation (Month 1, with or without CDSS use). This outcome evaluates whether the initial treatment strategy is maintained or modified between Month 0 and Month 1, including potential influence of CDSS use during the consultation | Month 1 |
| Cost-utility analysis of CDSS use | A cost-utility analysis will be conducted from a societal perspective over a 10-month period : at baseline (Month 0), Month 1, and Month 10 to evaluate the impact of CDSS use. Health-related quality of life will be assessed using the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L). The EQ-5D-5L descriptive system includes five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each with five response levels. Utility index values range from values below 0 (health states worse than death) to 1 (perfect health), with higher scores indicating better health status. Costs related to multiple sclerosis care will be collected over the study period (M0-M10) using patient diaries. Quality-adjusted life years (QALYs) will be estimated from EQ-5D-5L utility values and combined with cost data to perform the cost-utility analysis. | Month 0 to Month 10 |
| Patient-Reported Outcomes: Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) Score | Health-related quality of life will be assessed using validated patient-reported outcome (PRO) instrument : the Multiple Sclerosis-specific quality of life questionnaire (MusiQoL) at baseline (Month 0) and Month 10. The MusiQoL provides a disease-specific assessment of quality of life in multiple sclerosis. The MusiQoL global index score ranges from 0 to 100. Higher scores indicate better health-related quality of life. | Month 0 and Month 10 |
| Patient-Reported Outcomes: Health-Related Quality of life : 12-Item Short Form Health Survey (SF-12) Score | General health-related quality of life will be assessed using the 12-Item Short Form Health Survey (SF-12) at baseline (Month 0) and Month 10. It evaluates general health-related quality of life. The SF-12 generates Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. Scores generally range from 0 to 100. Higher scores indicate better health-related quality of life. | Month 0 and Month 10 |
| Clinician-Reported Usability of the Clinical Decision Support System (CDSS) | In the CDSS arm only, patient experience will be assessed using a dedicated 10-item questionnaire administered after a consultation supported by the Clinical Decision Support System (CDSS) at Month 1. Each item is rated on a 5-point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). The total score ranges from 10 to 50, with higher scores indicating a better patient experience with the CDSS-supported consultation. | Month 1 |
| Patient experience with CDSS use Patient Experience with Clinical Decision Support System (CDSS) Use | In the CDSS arm only, patient experience will be assessed using a dedicated 10-item questionnaire administered after a consultation supported by the Clinical Decision Support System (CDSS) at Month 1. Each item is rated on a 5-point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). The total score ranges from 10 to 50, with higher scores indicating a better patient experience with the CDSS-supported consultation. | Month 1 |
| Neurologist Experience with MRI Viewer Use During Consultation | Neurologists' experience with MRI viewer use during consultation will be assessed in both study arms (with or without CDSS use). Experience will be assessed using a dedicated 10-item questionnaire rated on a 5-point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). The total score ranges from 10 to 50, with higher scores indicating greater satisfaction and perceived usability of MRI visualization. All participating neurologists will complete the questionnaire. | Month 1 |
| Patient Experience with MRI Viewer Use During Consultation | Patient experience regarding MRI visualization using the viewer during neurological consultation will be assessed in both study arms. Experience will be assessed using a dedicated 10-item questionnaire rated on a 5-point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). The total score ranges from 10 to 50, with higher scores indicating greater satisfaction and improved understanding of MRI information. All included patients will complete the questionnaire. | Month 1 |
| Consultation duration | Impact of the (CDSS) on the duration of the neurological consultation. Consultation duration will be defined as the time (in minutes) elapsed between the start and end of the consultation (in minutes) at Month 1, conducted either with or without CDSS support | Month 1 |
| Device reliability | Reliability of the Clinical Decision Support System (CDSS) will be assessed by recording the number of device-related issues occurring during the study period. These issues include system failures, software bugs, interface malfunctions, security issues, interpretation errors, performance degradation, and connectivity problems. All CDSS-related malfunctions or operational issues will be recorded | Month 1 |
| Antibes Hospital | Antibes | 06606 | France |
|
| Bordeaux Hospital | Bordeaux | 33076 | France |
|
| CHU Brest | Brest | 29609 | France |
|
| Caen Hospital | Caen | 14000 | France |
|
| Clermont-Ferrand Hospital | Clermont-Ferrand | France |
|
| CHU Colmar | Colmar | France |
|
| Hôpital Henri Mondor | Créteil | 94000 | France |
|
| Dijon Hospital | Dijon | 21079 | France |
|
| Hôpital Emile Durkheim Epinal | Épinal | 88000 | France |
|
| Grenoble Alpes Hospital | Grenoble | 38700 | France |
|
| CHD Vendee | La Roche-sur-Yon | 85925 | France |
|
| Lille Hospital | Lille | 59037 | France |
|
| Hospices civils de Lyon | Lyon | 69500 | France |
|
| Marseille Hospital / La Timone | Marseille | 13385 | France |
|
| CHR Metz-Thionville / Mercy Hospital | Metz | 57530 | France |
|
| Montpellier Hospital | Montpellier | 34295 | France |
|
| Nancy Hospital | Nancy | 54035 | France |
|
| Nice Hospital | Nice | 06000 | France |
|
| Nimes Hospital | Nîmes | 30029 | France |
|
| Hopital Fondation ROTSCHILD | Paris | 75019 | France |
| CHIC Poissy | Poissy | 78303 | France |
|
| Poitiers Hospital | Poitiers | 86021 | France |
|
| Rennes Hospital | Rennes | 35000 | France |
|
| Rouen Hospital | Rouen | 76000 | France |
|
| Saint-Brieuc Hospital | Saint-Brieuc | 22027 | France |
|
| Groupement Hospitalier Rance Emeraude Saint Malo | St-Malo | France |
|
| Strasbourg Hospital | Strasbourg | 67200 | France |
|
| Toulouse Hospital | Toulouse | 31059 | France |
|
| tours Hospital | Tours | 37044 | France |
|
| Groupement Hospitalier Brocéliande Atlantique Vannes | Vannes | 56017 | France |
|
| ID | Term |
|---|---|
| D020529 | Multiple Sclerosis, Relapsing-Remitting |
| D009103 | Multiple Sclerosis |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided